Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT00956189
- Locations
- 🇨🇳
Yu-Li Hospital, Yu-Li, Hualien County, Taiwan
🇨🇳Yu-Li Veterans Hospital, Yu-Li, Hualien County, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 43
- Registration Number
- NCT00953745
- Locations
- 🇺🇸
Washington University in St. Louis, School of Medicine, Saint Louis, Missouri, United States
Trial of Aripiprazole in Trichotillomania
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 12
- Registration Number
- NCT00947154
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Metabolic Effects of Antipsychotic Substitution in Children
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT00910780
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2015-10-20
- Target Recruit Count
- 459
- Registration Number
- NCT00905307
- Locations
- 🇷🇸
Study Site (1), Belgrade, Serbia
🇷🇸Study Site (2), Belgrade, Serbia
🇷🇴Study Site (3), Bucuresti, Romania
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Veterans Medical Research Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT00895921
- Locations
- 🇺🇸
VA San Diego Healthcare System, San Diego, California, United States
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2013-12-02
- Target Recruit Count
- 64
- Registration Number
- NCT00857818
- Locations
- 🇨🇦
Local Institution, Quebec, Canada
Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT00845988
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00845026
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samara, Russian Federation
Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
- Conditions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2009-02-05
- Lead Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
- Target Recruit Count
- 25
- Registration Number
- NCT00837707
- Locations
- 🇨🇳
Taoyuan Mental Hospital, Taoyuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.